Phil Vickers talks new role as head of Longwood’s Solu after Faze shutdown; Regeneron CFO to retire in February September 15, 2023
Solu Therapeutics Appoints Philip Vickers, Ph.D., as President and Chief Executive Officer September 11, 2023
Solu Therapeutics Debuts with $31 Million in Seed Funding to Unlock Antibody-Intractable Cell Surface Targets August 1, 2023
